3.95
-2.95%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aligos Therapeutics
From its filings with the US Securities and Exchange Commission
Aligos Therapeutics is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ALGS. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $2.2m and a net loss of $24.2m. At that date it held total assets of $88.5m and shareholders' equity of $53.5m.
We are a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (e.g., SARS‑CoV‑2, SARS‑CoV, MERS‑CoV, and other related infections). The Aligos team has a demonstrated track record of success in drug development and medicinal chemistry in liver and viral diseases, resulting in three potential best‑in‑class drug candidates.
Our pipeline of drug candidates includes pevifoscorvir sodium (previously known as ALG-000184) for chronic HBV infection, ALG‑055009 for MASH and obesity, ALG‑097558 for coronavirus infections, and a portfolio of preclinical programs.
Pevifoscorvir sodium is our potential best‑/first‑in‑class Capsid Assembly Modulator (CAM‑E) for chronic HBV infection which has shown in preclinical testing to have enhanced pharmacologic properties vs. competitor CAM‑E drugs and greater hepatitis B virus deoxyribonucleic acid (HBV DNA) suppression compared to the standard of care, nucleos(t)ide analogs (NAs), and has shown multi-log10 reductions in viral antigens in a multi‑part Phase 1 clinical trial spanning up to 96 weeks of treatment. ALG‑055009 is our potential best‑in‑class thyroid hormone receptor beta (THR‑β) agonist for MASH and obesity with pharmacologic properties that appear to be enhanced based on data to date vs. competitor THR‑β agonists.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Oct 2020
- Employees
- 68
- Website
- aligos.com ↗
- Head office
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Lawrence BlattChairman of the Board, President, Chief Executive Officer, since 2018$2.1m
- Ms. Lesley CalhounChief Financial Officer, Chief Operating Officer, Executive Vice President$1.0m
- Dr. Julian SymonsExecutive Vice President, Chief Scientific Officer$834,517
- Dr. Hardean AchneckExecutive Vice President, Chief Medical Officer
- Ms. Margarita ChavezIndependent Director$66,904
- Dr. K. Peter HirthIndependent Director$68,234
- Dr. Bridget MartellIndependent Director$60,734
- Ms. Carole NuechterleinIndependent Director$16,984
- Dr. Heather PrestonIndependent Director$67,104
- Mr. James ScopaIndependent Director$75,734
- Mr. Jordyn TaraziVice President - Investor Relations and Corporate Communications, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 22
- Environment
- 24
- Social
- 23
- Governance
- 19
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aligos Therapeutics focuses on NASH and CHB with ALG-055009 and ALG-000184 for chronic liver diseases.
- The company utilizes small molecule and oligonucleotide platforms for pharmacologically optimized drug candidates.
- ALG-125755 and ALG-097558 target hepatitis B virus and coronavirus with validated clinical approaches.
Weaknesses
- Aligos Therapeutics has only 68 employees, limiting its operational capacity.
- The company's IPO in 2020 may indicate limited financial resources for expansion.
- The focus on NASH and CHB requires significant R&D investment without guaranteed outcomes.
Opportunities
- The growing market for chronic liver disease treatments offers potential for ALG-055009 and ALG-000184.
- ALG-125755 and ALG-097558 could benefit from increased demand for HBV and coronavirus therapies.
- Collaborations with larger biotech firms may enhance development of ALG-000184 and ALG-097558.
Threats
- Competition from established biotech companies in the NASH and CHB therapeutic space.
- Regulatory challenges may delay approval of ALG-055009 and ALG-125755.
- Economic downturns could reduce funding for clinical-stage biopharmaceutical companies like Aligos.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.